EndoQuest Robotics announced today that its proprietary surgical robot system will be installed at a major Boston hospital.
Houston-based EndoQuest’s endoluminal surgical (ELS) system will be installed at Brigham and Women’s Hospital (BWH) in Boston.
It’s the world’s first endoluminal surgical robotic system for scar-free upper and lower gastrointestinal surgery, according to a news release. The platform makes it possible for therapeutic endoscopists and surgeons to operate through a trans-oral or trans-anal approach.
EndoQuest is among MassDevice’s 16 surgical robotics companies you need to know. READ HERE
EndoQuest describes its system as an innovative advance in minimally invasive surgery. It designed the ELS system to combine the flexibility of conventional endoscopy with the advantages of traditional surgical techniques.
“Successful endoluminal surgery requires innovation in technology and procedural techniques,” said Dr. Christopher Thompson, professor of medicine and director of endoscopy, Brigham and Women’s Hospital. “The EndoQuest System is the world’s first fully robotic platform specifically designed for gastrointestinal tract surgery and can enable endoscopists to perform many procedures that are very challenging or not possible today.”
The technology allows for a range of surgeries by accessing target disease sites directly through existing lumens. The design features a proprietary endoscope serving as a flexible and steerable overtube supporting two surgical instruments and a videoscope.
EndoQuest’s ELS performs minimally invasive procedures using internal incisions that don’t result in visible scarring. EndoQuest said its system provides new levels of precision and control for techniques that weren’t previously possible.
“We are very pleased to partner with Brigham and Women’s Hospital, a global leader in innovation in endoluminal surgery, and look forward to working with them to advance the clinical and procedural development of the ELS System,” said Kurt Azarbarzin, CEO of EndoQuest Robotics. “We also hope to expand this relationship to include BWH as a center for our planned IDE clinical study in late 2023 and as our first Center of Excellence and training facility in the U.S.”